through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a

Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 16, 2025, American Radiolabeled Chem, 101 Arc Drive, Saint Louis, Missouri 63146—3502, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Ibogaine	Controlled substance	Drug code	Schedule
Lysergic acid diethylamide 7315 I Tetrahydrocannabinols 7370 I Dimethyltryptamine 7435 I 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I Dihydromorphone 9145 I Heroin 9200 I Normorphine 9313 I Amphetamine 1100 II Methamphetamine 1105 II Amobarbital 2125 II Phencyclidine 7471 II Phencyclotine 8501 II Cocaine 9041 I Codeine 9050 II Dihydrocodeine 9150 II Diydrocodone 9150 II Hydromorphone 9150 II Ecgonine 9150 II Hydrocodone 9180 II Hydrocodone 9180 II Hydrocodone 9180 II Meperidine 9230 II Metazocine 9240 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9333	Gamma Hydroxybutyric Acid	2010	1
Tetrahydrocannabinols 7370 Dimethyltryptamine 7435 1-1-(2-Thienylcyclohexyl]piperidine 9145 Dihydromorphone 9145 Heroin 9200 Normorphine 9313 Amphetamine 1100 Methamphetamine 1105 Amobarbital 2125 Phencyclidine 7471 Phencyclidine 7471 Phenylacetone 8501 Cocaine 9041 Codeine 9050 Dihydrocodeine 9120 Oxycodone 9143 Hydromorphone 9150 Eogonine 9150 Hydrocodone 9180 Metazocine 9230 Metazocine 9250 Dextropropoxyphene, bulk (non-dosage forms) 9273 Morphine 9333 Orjpavine 9333 Thebaine 9333 Oxymorphone 9652 Phenazocine 9715 Garfentanil <td>lbogaine</td> <td>7260</td> <td>1</td>	lbogaine	7260	1
Tetrahydrocannabinols 7370 Dimethyltryptamine 7435 1-1-(2-Thienylcyclohexyl]piperidine 9145 Dihydromorphone 9145 Heroin 9200 Normorphine 9313 Amphetamine 1100 Methamphetamine 1105 Amobarbital 2125 Phencyclidine 7471 Phencyclidine 7471 Phenylacetone 8501 Cocaine 9041 Codeine 9050 Dihydrocodeine 9120 Oxycodone 9143 Hydromorphone 9150 Eogonine 9150 Hydrocodone 9180 Metazocine 9230 Metazocine 9250 Dextropropoxyphene, bulk (non-dosage forms) 9273 Morphine 9333 Orjpavine 9333 Thebaine 9333 Oxymorphone 9652 Phenazocine 9715 Garfentanil <td></td> <td>7315</td> <td>1</td>		7315	1
Dimethyltryptamine 7435 1-[1-[2-Thienyl)cyclohexyl]piperidine 7470 Dihydromorphone 9145 Heroin 9200 Normorphine 9313 Amphetamine 1100 Methamphetamine 1105 Amobarbital 2125 Phencyclidine 7471 Phenylacetone 8501 Cocaine 9041 Codeine 9050 Dihydrocodeine 9050 Oxycodone 9120 Hydromorphone 9150 Ecgonine 9180 Hydrocodone 9180 Meperidine 9230 Metazocine 9240 Methadone 9250 Dextropropoxyphene, bulk (non-dosage forms) 9273 Morphine 9300 Oripavine 9333 Thebaine 9333		7370	1
1-[1-(2-Tinenyl)cyclohexyl]piperidine 7470 I Dihydromorphone 9145 I Heroin 9200 I Normorphine 9313 I Amphetamine 9313 I Methamphetamine 1105 II Amobarbital 2125 II Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeline 9050 II Dihydrocodeine 9050 II Oxycodone 9143 II Hydrocorphone 9150 II Ecgonine 9150 II Hydrocodone 9180 II Hydrocodone 9193 II Metazocine 9230 II Metazocine 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9330 II Oripavine 9333 II Thebaine 9933 II Oxymorphone 9952	Dimethyltryptamine	7435	1
Dihydromorphone 9145 1 Heroin 9200 1 Normorphine 3313 1 Amphetamine 1100 II Methamphetamine 2125 II Amobarbital 2125 II Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9050 II Oxycodone 9120 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9330 II Oripavine 9333 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9652 II Phenazocine 9743 II	1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	1
Heroin 9200 1 Normorphine 9313 1 Amphetamine 1100 1 Methamphetamine 1105 1 Amobarbital 2125 1 Phencyclidine 7471 1 Phenylacetone 8501 1 Cocaine 9041 1 Codeine 9050 1 Dihydrocodeine 9050 1 Dihydrocodeine 9120 1 Oxycodone 9143 1 Hydromorphone 9150 1 Ecgonine 9150 1 Ergonine 9150 1 Hydrocodone 9193 1 Meperidine 9193 1 Meperidine 9230 1 Metazocine 9240 1 Methadone 9250 1 Dextropropoxyphene, bulk (non-dosage forms) 9273 1 Morphine 9300 1 Oripavine 9333 1 Oxymorphone 9333 1 Oxymorphone 9333 1 Oxymorphone 9333 1 Oxymorphone 9652 1 Phenazocine 9713 1 Carfentanil 9743 1	Dihydromorphone	9145	1
Normorphine 9313 I Amphetamine 1100 II Methamphetamine 2125 II Amobarbital 2125 II Phencyclidine 7471 II Phenplacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydrocorphone 9150 II Ecgonine 9180 II Hydrocodone 9180 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9333 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanii 9743 II		9200	1
Amphetamine 1100 II Methamphetamine 1105 II Amobarbital 2125 II Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II		9313	1
Methamphetamine 1105 II Amobarbital 2125 II Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9130 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9180 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9675 II Carfentanil 9743 II		1100	П
Amobarbital 2125 II Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9180 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9330 II Oripavine 9333 II Thebaine 9652 II Phenazocine 9715 II Carfentanil 9743 II		1105	П
Phencyclidine 7471 II Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9330 II Oripavine 9333 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Phenylacetone 8501 II Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Cocaine 9041 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Oxycodone 9143 II Hydromorphone 9150 II Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Hydromorphone 9150 Ecgonine 9180 Hydrocodone 9193 Meperidine 9230 Metazocine 9240 Methadone 9250 Dextropropoxyphene, bulk (non-dosage forms) 9273 Morphine 9300 Oripavine 9330 Thebaine 9333 Oxymorphone 9652 Phenazocine 9715 Carfentanil 9743			
Ecgonine 9180 II Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Hydrocodone 9193 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Metazocine 9240 II Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Methadone 9250 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Oripavine 9330 I Thebaine 9333 I Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II	, , , , , , , , , , , , , , , , , , , ,		
Thebaine 9333 II Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Oxymorphone 9652 II Phenazocine 9715 II Carfentanil 9743 II			
Phenazocine 9715 II Carfentanil 9743 II			
Carfentanil	·		
	Fentanyl	9801	ii

manufacture the listed controlled substances for internal use as intermediates or for sale to its customers. The company plans to manufacture small quantities of the above listed controlled substances as radiolabeled compounds for biochemical research. In reference to drug code 7370 (Tetrahydrocannabinols), the company

The company plans to bulk

plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–11247 Filed 6–17–25; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF LABOR

Occupational Safety and Health Administration

[Docket No. OSHA-2016-0005]

Notice of Meeting

AGENCY: Occupational Safety and Health Administration, Labor.

ACTION: Notice of Public Meeting.

SUMMARY: This notice is to advise interested persons that OSHA will conduct a virtual public meeting on June 24, 2025, in advance of the 48th session of the United Nations Sub-Committee of Experts on the Globally Harmonized System of Classification and Labelling of Chemicals (UNSCEGHS) to be held as an in-person meeting July 7–9, 2025, in Geneva, Switzerland. OSHA, along with the U.S. Interagency Globally Harmonized System of Classification and Labelling

of Chemicals (GHS) Coordinating

Group, plans to consider the comments and information gathered at the June 24, 2025, public meeting when developing the U.S. Government positions for the UNSCEGHS meeting July 7–9, 2025.

DATES: OSHA's virtual public meeting will take place on June 24, 2025. Specific information for the meeting will be posted when available on the OSHA website at https://www.osha.gov/hazcom/international#meeting-notice.

ADDRESSES: This meeting will be held virtually and broadcast by the Department of Labor, in Washington, DC, on June 24, 2025, from 1:00–4:00 p.m.

Written Comments: Interested parties may submit written comments until July 7, 2025, on the Working and Informal Papers for the 48th session of the UNSCEGHS to the docket established for International/Globally Harmonized System (GHS) efforts at: http://www.regulations.gov, Docket No. OSHA-2016-0005.

Registration to Attend and/or to Participate in the Public Meeting: Registration information and how to participate for the OSHA session will be posted when available on the OSHA website at https://www.osha.gov/ hazcom/international#meeting-notice.

If you need interpretation or alternative formats or services because of a disability, such as sign language or other ancillary aids, please contact the person listed in the FOR FURTHER INFORMATION CONTACT section.

FOR FURTHER INFORMATION CONTACT:

Please contact Ms. Janet Carter, OSHA Directorate of Standards and Guidance, Department of Labor, telephone: (202) 693–2370, email *carter.janet@dol.gov*.

supplementary information: OSHA will conduct a virtual public meeting on June 24, 2025, to discuss proposals in preparation for the in-person 48th session of the UNSCEGHS July 7–9, 2025, in Geneva, Switzerland. Advance registration information for OSHA's virtual public meeting will be posted on the OSHA website at https://www.osha.gov/hazcom/international#meeting-notice.

OSHA will solicit public input on U.S. government positions regarding proposals submitted by member countries until July 7, 2025. Information on the work of the UNSCEGHS, including meeting agendas, working and informal papers, reports, and documents from previous sessions can be found on the United Nations Economic Commission for Europe (UNECE) Transport Division website located at: https://unece.org/info/Transport/Dangerous-Goods/events/391043.

Authority and Signature

Amanda Laihow, Acting Assistant Secretary of Labor for Occupational Safety and Health, U.S. Department of Labor, authorized the preparation of this notice under the authority granted by sections 4, 6, and 8 of the Occupational Safety and Health Act of 1970 (29 U.S.C. 653, 655, 657), and Secretary's Order 1–2012 (77 FR 3912) (Jan. 25, 2012).

Signed at Washington, DC, on June 13, 2025.

Amanda Laihow,

Acting Assistant Secretary of Labor for Occupational Safety and Health.

[FR Doc. 2025–11179 Filed 6–17–25; 8:45 am]

BILLING CODE 4510-26-P

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

National Endowment for the Arts

National Council on the Arts 216th Meeting

AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities.

ACTION: Notice of Meeting.

SUMMARY: Pursuant to section 10 (a) (2) of the Federal Advisory Committee Act, as amended, notice is hereby given that a meeting of the National Council on the Arts will be held open to the public by videoconference. An additional session will be closed to the public for reasons stated below.

DATES: See the **SUPPLEMENTARY INFORMATION** section for meeting time and date. The meeting will occur in Eastern time and the ending time is approximate.

ADDRESSES: The National Endowment for the Arts, Constitution Center, 400 Seventh Street SW, Washington, DC 20560. This meeting will be held by videoconference. Public portions of the meeting will be webcast. Please see arts.gov for the most up-to-date information.

FOR FURTHER INFORMATION CONTACT: Liz Auclair, Office of Public Affairs, National Endowment for the Arts, Washington, DC 20506, at 202/682–5744.

SUPPLEMENTARY INFORMATION: The meeting will take place on July 10, 2025.

Open Session: July 10, 2025; 1:30 p.m. Location: Videoconference. There will be a discussion of general agency business. This session will be held open to the public by videoconference. To view the webcasting of this session of the meeting, go to: https://www.arts.gov/ . If you need special accommodations due to a disability, please contact Office of Civil Rights, National Endowment for the Arts, Constitution Center, 400 7th St. SW, Washington, DC 20506, 202/ 682-5454, Voice/T.T.Y. 202/682-5496, at least seven (7) days prior to the meeting. If, in the course of the open session discussion, it becomes necessary for the Council to discuss non-public commercial or financial information of intrinsic value, the Council will go into closed session pursuant to subsection (c)(4) of the Government in the Sunshine Act, 5 U.S.C. 552b, and in accordance with the March 11, 2022. determination of the Chair. Additionally, discussion concerning purely personal information about individuals, such as personal

biographical and salary data or medical information, may be conducted by the Council in closed session in accordance with subsection (c) (6) of 5 U.S.C. 552b.

Closed Session: July 10, 2025; 10:00 a.m. to 11:00 a.m. Location: Videoconference. This meeting session will be closed to the public for the aforementioned reasons.

Date: June 13, 2025.

Lara Allee.

Program Analyst, Office of Guidelines and Panel Operations.

[FR Doc. 2025–11177 Filed 6–17–25; 8:45 am]

POSTAL REGULATORY COMMISSION

[Docket Nos. K2025–343; K2025–361; K2025–626; MC2025–1518 and K2025–1513; MC2025–1519 and K2025–1514; MC2025–1520 and K2025–1515; MC2025–1521 and K2025–1516; MC2025–1522 and K2025–1517]

New Postal Products

AGENCY: Postal Regulatory Commission. **ACTION:** Notice.

SUMMARY: The Commission is noticing a recent Postal Service filing for the Commission's consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps.

DATES: Comments are due: June 23, 2025.

ADDRESSES: Submit comments electronically via the Commission's Filing Online system at https://www.prc.gov. Those who cannot submit comments electronically should contact the person identified in the FOR FURTHER INFORMATION CONTACT section by telephone for advice on filing alternatives.

FOR FURTHER INFORMATION CONTACT: David A. Trissell, General Counsel, at

202-789-6820. **SUPPLEMENTARY INFORMATION:**

Table of Contents

I. Introduction II. Public Proceeding(s) III. Summary Proceeding(s)

I. Introduction

Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an